Frequently Asked Questions
The major factor for the Hereditary Testing market is the rising prevalence of genetic disorders such as cancer and rising awareness of the benefits of genetic testing. The increasing need to find a cure for cancer creates demand for global genetic testing, which is expected to drive the hereditary testing market. The advancement in hereditary technology and rapid expansion in the biotechnology sector is expected to increase the growth. Additionally, there are many better product manufacturers a
The global hereditary testing market is anticipated to grow at a substantial CAGR of 6.10% in the upcoming years. The global hereditary testing market was estimated to be worth USD 5,729.5 Million in 2021 and was expected to be worth USD 8,173.51 Million by 2028.
In 2021, North America dominated with the highest market share in the global hereditary testing market. The rapid growth of tubes due to awareness, the high incident rate of cancer and favorable compensation policies are expected to grow the North American Hereditary Testing market. Furthermore, with the increasing number of manufacturing facilities, the product is available at the lowest cost, and technological advancement is expected to support the North American region’s Hereditary Testing ma
The main competitors dominating the global hereditary testing market include Myriad Genetics Inc., Invitae Corporation, Illumina Inc., Natera Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, CooperSurgical Inc., Agilent Technologies Inc., and Thermo Fisher Scientific Inc.
In 2021, the molecular testing segment dominated and accounted for the largest share of the hereditary testing market. Genetic analysis is mostly utilized techniques of hereditary genetic counseling, which requires molecular testing equipment.